Lexipafant
| Code | Size | Price |
|---|
| TAR-T27821-5mg | 5mg | £930.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27821-50mg | 50mg | £1,821.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27821-100mg | 100mg | £2,319.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Lexipafant is a platelet-activating factor (PAF) receptor antagonist.
CAS:
139133-26-9
Formula:
C24H32N4O4S
Molecular Weight:
472.6
Purity:
0.98
SMILES:
CCOC(=O)[C@H](CC(C)C)N(C)S(=O)(=O)c1ccc(CCn2c(C)nc3cnccc23)cc1
References
1. Ozt?rk H, Ozt?rk H, Dokucu AI, Otcu S. Effects of lexipafant (BB-882), a platelet activating factor receptor antagonist, on liver damage due to bile duct ligation in rats. Acta Gastroenterol Belg. 2006 Apr-Jun;69(2):197-202. PubMed PMID: 16929615.
2. Aldemir M, Bo?nak M, Al B, B?y?kbayram H, Ta?yildiz I. Effects of molsidomine and lexipafant in hepatic ischaemia--reperfusion injury. Injury. 2004 Mar;35(3):232-7. PubMed PMID: 15124788.
3. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, Toh SK, Skaife P, Leeder PC, Wilson P, Larvin M, Curtis LD. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut. 2001 Jan;48(1):62-9. PubMed PMID: 11115824; PubMed Central PMCID: PMC1728186.
4. B?rjesson A, Wang X, Sun Z, Inghammar M, Truedsson L, Andersson R. Early treatment with lexipafant, a platelet-activating factor-receptor antagonist, is not sufficient to prevent pulmonary endothelial damage after intestinal ischaemia and reperfusion in rats. Dig Liver Dis. 2002 Mar;34(3):190-6. PubMed PMID: 11990391.